Outlook Therapeutics, Inc.

DB:41O Stock Report

Market Cap: €114.3m

Outlook Therapeutics Valuation

Is 41O undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 41O when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 41O's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 41O's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 41O?

Key metric: As 41O is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 41O. This is calculated by dividing 41O's market cap by their current book value.
What is 41O's PB Ratio?
PB Ratio-1.4x
Book-US$83.67m
Market CapUS$118.99m

Price to Book Ratio vs Peers

How does 41O's PB Ratio compare to its peers?

The above table shows the PB ratio for 41O vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average12.3x
HPHA Heidelberg Pharma
2.9x-33.0%€103.9m
2INV 2invest
1xn/a€63.8m
VSC 4SC
44xn/a€48.2m
MDG1 Medigene
1.2x-4.1%€22.6m
41O Outlook Therapeutics
n/a56.4%€119.0m

Price-To-Book vs Peers: 41O has negative equity and a Price-To-Book Ratio (-1.4x) compared to the peer average (12.3x).

Price to Book Ratio vs Industry

How does 41O's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
41O is unprofitableIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 41O has negative equity and a Price-To-Book Ratio (-1.4x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 41O's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

41O PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-1.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 41O's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 41O forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.82
€37.07
+669.2%
22.4%€49.75€28.16n/a6
Nov ’25€5.35
€36.45
+581.3%
22.4%€48.91€27.68n/a6
Oct ’25€4.88
€33.82
+593.0%
25.7%€47.89€22.59n/a7
Sep ’25€6.55
€33.61
+413.1%
26.4%€47.95€22.62n/a7
Aug ’25€7.10
€35.55
+400.7%
29.8%€55.50€23.13n/a7
Jul ’25€6.75
€35.55
+426.6%
29.8%€55.50€23.13n/a7
Jun ’25€6.65
€35.55
+434.5%
29.8%€55.50€23.13n/a7
May ’25€8.35
€36.82
+340.9%
29.0%€55.42€23.09n/a7
Apr ’25€9.48
€36.82
+288.6%
29.0%€55.42€23.09n/a7
Mar ’25€7.60
€40.97
+439.1%
27.3%€55.37€27.68n/a6
Feb ’25€6.88
€41.73
+506.6%
56.4%€92.26€18.45n/a6
Jan ’25€7.32
€45.18
+517.1%
60.0%€90.35€18.07n/a4
Dec ’24€8.36
€25.65
+206.8%
30.2%€37.30€18.65n/a4
Nov ’24€11.60
€21.03
+81.3%
19.2%€28.04€18.69€5.354
Oct ’24€3.92
€21.03
+436.5%
19.2%€28.04€18.69€4.884
Sep ’24€4.20
€48.39
+1,052.1%
107.2%€138.26€18.43€6.554
Aug ’24€31.00
€115.80
+273.6%
28.0%€178.16€80.17€7.108
Jul ’24€29.60
€125.65
+324.5%
27.5%€187.14€84.21€6.757
Jun ’24€29.60
€125.65
+324.5%
27.5%€187.14€84.21€6.657
May ’24€18.90
€121.18
+541.1%
29.2%€183.40€73.36€8.357
Apr ’24€19.63
€126.07
+542.3%
28.5%€183.38€73.35€9.486
Mar ’24€20.17
€115.44
+472.4%
34.4%€186.20€74.48€7.605
Feb ’24€20.70
€127.77
+517.3%
27.0%€187.90€93.95€6.885
Jan ’24€19.62
€131.19
+568.8%
23.9%€187.42€93.71€7.325
Dec ’23€19.56
€145.76
+645.2%
20.4%€202.44€121.46€8.365
Nov ’23€22.93
€145.76
+535.7%
20.4%€202.44€121.46€11.605

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

5.1%

1Y

22.9%